Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)WithdrawnNCT05604417
What this trial is testing

Zandelisib + Tazemetostat in R/R Follicular Lymphoma

Who this might be right for
Relapsed Follicular LymphomaRefractory Follicular Lymphoma
Jacob Soumerai, MD
Very early researchLooking for participantsNCT06045091
What this trial is testing

To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL

Who this might be right for
Multiple MyelomaPlasma Cell Leukemia
Hrain Biotechnology Co., Ltd. 18
Testing effectiveness (Phase 2)Active Not RecruitingNCT03373097
What this trial is testing

Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors

Who this might be right for
NeuroblastomaNeuroblastoma RecurrentGD2-positive Solid Tumors+3 more
Bambino Gesù Hospital and Research Institute 42
Early research (Phase 1)Study completedNCT05011097
What this trial is testing

A Phase I Clinical Trial of Y150 in the Treatment of Relapsed or Refractory Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Wuhan YZY Biopharma Co., Ltd. 20
Large-scale testing (Phase 3)Ended earlyNCT00416910
What this trial is testing

Combination Chemotherapy With or Without G-CSF in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

Who this might be right for
Chronic Lymphocytic Leukemia
German CLL Study Group 83
Testing effectiveness (Phase 2)Study completedNCT00951613
What this trial is testing

NK012 in Patients With Relapsed Small Cell Lung Cancer

Who this might be right for
Small Cell Lung Cancer
Nippon Kayaku Co., Ltd. 72
Testing effectiveness (Phase 2)UnknownNCT05274997
What this trial is testing

A Phase II Study of Linperlisib (YY-20394) in Patients With Relapsed or Refractory Peripheral T/NK Cell Lymphoma

Who this might be right for
Peripheral T/NK Cell Lymphoma (R/R PTCL)
Shanghai YingLi Pharmaceutical Co. Ltd. 97
Testing effectiveness (Phase 2)Ended earlyNCT01034410
What this trial is testing

AS1411 Combined With Cytarabine in the Treatment of Patients With Primary Refractory or Relapsed Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Antisoma Research 90
Testing effectiveness (Phase 2)Active Not RecruitingNCT06035497
What this trial is testing

Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

Who this might be right for
Relapsed or Refractory T-cell Lymphomas
Bristol-Myers Squibb 85
Testing effectiveness (Phase 2)Ended earlyNCT05272813
What this trial is testing

Investigate the Efficacy and Safety of MS-553 in CLL/SLL

Who this might be right for
Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Shenzhen MingSight Relin Pharmaceuticals Co., Ltd. 13
Testing effectiveness (Phase 2)Ended earlyNCT06268574
What this trial is testing

Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML

Who this might be right for
Acute Myeloid Leukemia (AML)High-risk Myelodysplastic Syndrome
Ryvu Therapeutics SA 62
Early research (Phase 1)Study completedNCT01703572
What this trial is testing

A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies

Who this might be right for
Relapsed or Refractory Lymphoid Malignancies
OncoMed Pharmaceuticals, Inc. 24
Testing effectiveness (Phase 2)Ended earlyNCT03340883
What this trial is testing

Safety and Tolerability of BION-1301 in Adults With Relapsed or Refractory Multiple Myeloma (MM)

Who this might be right for
Multiple Myeloma
Chinook Therapeutics, Inc. 21
Testing effectiveness (Phase 2)UnknownNCT01300156
What this trial is testing

Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL)

Who this might be right for
Hodgkin's Lymphoma
National Cancer Center, Korea 37
Early research (Phase 1)Looking for participantsNCT06830031
What this trial is testing

Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma

Who this might be right for
Diffuse Large B-cell-lymphomaDLBCL, Nos Genetic SubtypesFollicular Lymphoma Grade 3B+3 more
Shanghai Exuma Biotechnology Ltd. 18
Testing effectiveness (Phase 2)Study completedNCT00083694
What this trial is testing

Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia

Who this might be right for
Leukemia
University of Arkansas 25
Testing effectiveness (Phase 2)Study completedNCT00793572
What this trial is testing

Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma

Who this might be right for
Refractory Plasma Cell Myeloma
Fred Hutchinson Cancer Center 32
Testing effectiveness (Phase 2)WithdrawnNCT04535102
What this trial is testing

POLA+BR for Relapsed or Refractory DLBCL

Who this might be right for
Diffuse Large B Cell Lymphoma
University of Colorado, Denver
Early research (Phase 1)Study completedNCT01625351
What this trial is testing

CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas

Who this might be right for
Ewing SarcomaGastrointestinal TumorGerm Cell Tumor+10 more
St. Jude Children's Research Hospital 23
Testing effectiveness (Phase 2)Looking for participantsNCT07502287
What this trial is testing

Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma

Who this might be right for
Relapsed NeuroblastomaRefractory NeuroblastomaHigh-Risk Neuroblastoma+1 more
Beijing Biotech 36
Next Page